-
Biosimilars Market 2024-2031 Market Analysis: Growth Trends, Demand, and Forecast Overview | Biogen Idec Inc
04 Nov 2024 22:19 GMT
… AG
◘ Merck & Co. Inc.
◘ Biogen Idec Inc
◘ Coherus BioSciences
◘ Stada Arzneimittel …
-
Biosimilars Market Projected to Witness Huge Growth by 2024-2031 | Biogen Idec Inc, Celltrion Healthcare Co., Ltd
08 Oct 2024 11:09 GMT
… AG
◘ Merck & Co. Inc.
◘ Biogen Idec Inc
◘ Coherus BioSciences
◘ Stada Arzneimittel …
-
Multiple Sclerosis Therapeutics Market Expected to Expand at a Steady 2024-2031 | Bayer AG, Pfizer, Inc., Biogen Idec
10 Apr 2024 07:23 GMT
… .A.
◘ Bayer AG
◘ Pfizer Inc.
◘ Biogen Idec
◘ Merck & Co. Inc.
◘ AbbVie …
-
Autoinjectors Market May See a Big Move | Ypsomed, Biogen Idec, Gerresheimer
02 Feb 2024 22:13 GMT
… Medical, Teva Pharmaceutical Industries, Ypsomed, Biogen Idec, Owen Mumford, Consort Medical, AbbVie … , Teva Pharmaceutical Industries, and Ypsomed, Biogen Idec, Owen Mumford, Consort Medical, Abbvie …
-
Biogen Idec
28 Aug 2023 04:28 GMT
-
Neuropathic Pain Market Set to Witness Significant Growth by 2024-2031 | Pfizer, Inc., Johnson & Johnson Services
20 Dec 2024 11:39 GMT
… Lily and Company
• GlaxoSmithKline PLC
• Biogen Idec.
• Bristol-Myers Squibb
• Baxter Healthcare …
-
Finally, a New Drug for Posttraumatic Stress Disorder?
20 Dec 2024 11:11 GMT
… for Otsuka America Pharmaceutical, Aptinyx, Biogen, IDEC, Bionomics Ltd, Boehringer Ingelheim International …
-
The Rise of Autoinjectors Market: Innovation in Self-Administered Therapies | Ypsomed, Biogen Idec, Abbvie, Gerresheimer
12 Jul 2023 20:58 GMT
… Medical, Teva Pharmaceutical Industries, Ypsomed, Biogen Idec, Owen Mumford, Consort Medical, Abbvie … , Teva Pharmaceutical Industries, and Ypsomed, Biogen Idec, Owen Mumford, Consort Medical, Abbvie …
-
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development
10 Dec 2024 12:07 GMT
… of New Product Commercialization at Biogen Idec. Before joining industry, Jim was …
-
When good stocks turn bad
09 Dec 2024 07:30 GMT
… product cycles (Gilead, Bristol-Myers, Biogen Idec, Pfizer). In 2014 Gilead sold … an exciting oncology portfolio; and Biogen Idec’s portfolio of multiple sclerosis …